Posso obtê-lo?
Sim, se um médico decidir que é adequado para si. Vitaros está autorizado na UE e pode ser prescrito após uma avaliação médica.
VitarosApenas com receita
Consulta médica online para Vitaros.
Um médico licenciado na UE analisa o seu caso e, se for elegível, emite uma receita eletrónica válida em qualquer farmácia da UE ao abrigo da Diretiva 2011/24/UE.
- A non-PDE5 route
- Direct, local action
- An option when oral PDE5s don't work or aren't allowed
Iniciar consultaIniciar consulta · 35 €
Reembolso total se uma avaliação não for aprovada · A medicação, se for prescrita, é dispensada e paga separadamente numa farmácia.
EM TERMOS SIMPLES
O que é Vitaros e como obter tratamento
O alprostadil é uma cópia da prostaglandina E1, uma substância produzida naturalmente pelo corpo que alarga os vasos sanguíneos. Ao contrário dos comprimidos, é aplicado diretamente no pénis: como creme na ponta, como injeção na parte lateral do corpo do pénis ou como um pequeno grânulo colocado na uretra. Assim, atua diretamente nos vasos sanguíneos. Está autorizado nos países da UE para a disfunção erétil desde 1994 como injeção e desde 2014 como creme. Como atua localmente, os principais efeitos indesejáveis também são locais: ardor, dor ou vermelhidão no local da aplicação e, raramente, uma ereção que dura demasiado tempo e exige assistência médica urgente.
Vitaros está autorizado para utilização na UE desde 29 de novembro de 1994. Por isso, um médico habilitado pode prescrevê-lo quando for clinicamente adequado para si.
O que posso tomar em alternativa?
Os nossos médicos avaliam todas as opções de Saúde sexual e recomendam a que melhor se adapta ao seu historial clínico e aos seus objetivos.
Veja todas as opções de Saúde sexualO que mostram os estudos?
Todos os ensaios sobre Vitaros estão indicados abaixo, com o número de participantes e a indicação de que os resultados foram revistos por pares ou de que são apenas um anúncio da empresa.
Ir para os estudosEVIDÊNCIA VERIFICADA
Vitaros: guia de evidência e regulamentação.
O QUE É
Como atua
Alprostadil is a man-made copy of a natural body chemical (prostaglandin E1) that is applied to or injected into the penis, where it widens the blood vessels directly so blood flows in.
FASE DE DESENVOLVIMENTO
Medicamento autorizado na UE
Registo de ensaios4 ensaios registados
Cada identificador NCT liga ao registo ClinicalTrials.gov. Um resultado comunicado não equivale a uma publicação revista por pares.
| ENSAIO / NCT | POPULAÇÃO | PARTICIPANTES | ESTADO | RESULTADO / CONCLUSÃO |
|---|---|---|---|---|
| Integrated analysis of two multicentre, double-blind, parallel-group topical-cream studies | Men with an IIEF erectile function domain score of 25 or less, including men with diabetes and men taking organic nitrates | 1,732 | Com resultados | 2006-08-01 |
| Alprostadil Study Group — intracavernosal dose-response study | Men with erectile dysfunction of vasculogenic, neurogenic, psychogenic and mixed causes | 296 | Com resultados | 1996-04-04 |
| Alprostadil Study Group — six-month intracavernosal self-injection study | Men with erectile dysfunction of mixed causes | 683 | Com resultados | 1996-04-04 |
| MUSE Study Group — transurethral alprostadil, double-blind placebo-controlled trial | Men aged 27-88 with chronic erectile dysfunction from various organic causes | 1,511 | Com resultados | 1997-01-02 |
O que os estudos comunicaram
Os resultados estão separados por fonte e grau de evidência para não confundir dados científicos com anúncios do fabricante.
Revisto por pares
Padma-Nathan H, Yeager JL. An integrated analysis of alprostadil topical cream for the treatment of erectile dysfunction in 1732 patients. Urology 2006;68(2):386-391. doi:10.1016/j.urology.2006.02.027 (PMID 16904458)| DOSE OU GRUPO | ALTERAÇÃO MÉDIA DO PESO | SEMANAS |
|---|---|---|
| 100 microgram cream (n=434) | IIEF erectile function domain change from baseline +1.6 points vs -0.7 on placebo (p<0.001) | 12 |
| 200 microgram cream (n=430) | IIEF erectile function domain change from baseline +2.5 points vs -0.7 on placebo (p<0.001) | 12 |
| 300 microgram cream (n=434) | IIEF erectile function domain change from baseline +2.4 points vs -0.7 on placebo (p<0.001) | 12 |
The IIEF changes are small in absolute terms and the authors describe the SEP2 and SEP3 improvements as slight though statistically significant; the studies ran for 12 weeks and cover the topical cream only, not the injected or intraurethral forms.
Fontes
Última revisão 2026-07-27
- AEMPS CIMA — Caverject 20 microgramos (alprostadil, intracavernosal injection), reg. 60535, first authorised in Spain 29 November 1994, indicated for erectile dysfunction
- AEMPS CIMA — Virirec 3 mg/g crema (alprostadil topical), reg. 78357, first authorised April 2014; the same cream was approved via the EU decentralised procedure as Vitaros in 2013
- Urology 2006 — Integrated analysis of alprostadil topical cream in 1,732 patients (PMID 16904458)
- N Engl J Med 1996 — Efficacy and safety of intracavernosal alprostadil (PMID 8596569)
- N Engl J Med 1997 — Treatment of men with erectile dysfunction with transurethral alprostadil, MUSE Study Group (PMID 8970933)
SINAIS DE SEGURANÇA IDENTIFICADOS
O que foi comunicado com Vitaros.
Application-site burning, penile pain and redness (cream)
Penile burning, penile pain, penile erythema, genital pain and genital discomfort are all listed as common in the EU product information for alprostadil 3 mg/g cream. In the clinical trial the withdrawal rate was 30% in the 300 microgram group compared with 20% in the 200 microgram group.
Injection-site pain (intracavernosal)
Penile pain is listed as very common in the EU product information for alprostadil injection. In the six-month self-injection study, usually mild penile pain occurred in 50% of men at some time but after only 11% of injections.
Prolonged erection and priapism (intracavernosal)
In the EU product information for alprostadil injection, a prolonged erection lasting 4 to 6 hours developed in 4% of patients and priapism (a painful erection lasting more than 6 hours) in 0.4%. In the six-month self-injection study, prolonged erections occurred in 5% of men and priapism in 1%.
Prolonged erection and priapism (cream)
Listed as uncommon in the EU product information for alprostadil cream. Priapism was seen in 1 patient (0.06%) across the two 3-month studies and in 5 patients (0.4%) in the study lasting more than 6 months. An erection lasting more than 4 hours needs immediate medical help, because untreated priapism can permanently damage erectile tissue.
Penile fibrosis (intracavernosal)
Penile fibrosis, including angulation, fibrotic nodules and Peyronie's disease, was reported in 3% of clinical-trial patients in the EU product information for alprostadil injection, rising to about 8% in a self-administration study of up to 18 months. Injection-site haematoma was reported by 3% and bruising by 2%.
Dizziness and fainting
In the phase 3 cream studies, symptomatic low blood pressure (dizziness) and fainting occurred in 0.4%, 0.4% and 0.5% of patients on the 100, 200 and 300 microgram doses. Patients are advised not to drive or do hazardous tasks until they know how they react.
Effects on a female partner
Vulvovaginal burning and vaginitis are listed as common reactions in female partners in the EU product information for alprostadil cream.
Penile pain (intraurethral)
In the transurethral pivotal trial, mild penile pain was the most common side effect, occurring after 10.8% of treatments; in-clinic low blood pressure occurred in 3.3% of men, and no man had priapism or penile fibrosis.
FormaCreme uretral ou injeção
FrequênciaConforme necessário
ResultadosDirect local action
O que paga à Hi-Doctor35 € pontual
EM 60 SEGUNDOS
Vitaros num relance
- A prostaglandin E1 medicine that widens the blood vessels inside the penis
- Adult men whose erectile dysfunction is unsuited to, or not helped by, oral tablets
- Given as a cream at the tip of the penis, a urethral pellet, or an injection
- An erection lasting 4 hours or more is priapism, and it is a medical emergency
- Hi-Doctor consultation fee; the medicine is paid separately at a pharmacy
DADOS DA MARCA
Vitaros num relance
- TITULAR DA AUTORIZAÇÃO DE INTRODUÇÃO NO MERCADO
- The Simple Pharma Company Limited
- APRESENTAÇÕES
- 3 mg/g cream (300 micrograms of alprostadil per 100 mg of cream) in single-dose AccuDose applicators
Sobre o tratamento
O que é Vitaros?
Vitaros contém a substância ativa alprostadil.
Substância ativa: Alprostadil · Dosagens: Cream 3 mg/g on demand
Alprostadil is a prostaglandin E1 that directly dilates the blood vessels of the penis. It's considered when oral PDE5 inhibitors are ineffective or contraindicated.
It's administered as a urethral cream or an intracavernous injection, under medical instruction — each route has its own efficacy and tolerability profile. Correct technique matters, and the doctor explains the protocol and the warning signs.
COMO ATUA
O que Vitaros faz no seu corpo
Rather than blocking an enzyme, alprostadil acts directly on the penile blood vessels, dilating them locally — no PDE5 pathway involved, so it can work where oral options don't.
A copy of prostaglandin E1
Alprostadil is chemically identical to prostaglandin E1, a signalling substance the body already makes. It is not swallowed. It is placed into or onto the penis itself, so it acts on the erectile tissue at the site rather than circulating through the whole body first.
Cavernosal muscle relaxes
The drug relaxes the smooth muscle of the corpora cavernosa, the two spongy cylinders that run the length of the penis, and widens the cavernosal arteries feeding them. Blood flow into the erectile tissue rises, and that increase in flow is what produces rigidity.
It does not need arousal
Because it acts on the tissue directly, alprostadil does not depend on the nitric oxide signal that sexual stimulation produces. In clinic testing it created erections on its own. That is the core difference from tablets, and it is also why an erection can outlast the encounter.
Como ajuda
How it helps.
A different pathway
Works directly on the blood vessels — not through the PDE5 enzyme.
Local application
Applied where it acts, shortly before intercourse.
Guided by your doctor
Administration technique and warning signs are explained before you start.
O que esperar
How to use it.
Prescribed with clear administration instructions. Your doctor explains the protocol, and follow-up happens through your account chat.
- Prescribed with clear administration instructions
- Applied shortly before intercourse
- Correct technique matters — your doctor explains it
- Follow-up and questions through your account chat
Forms your doctor can prescribe
- Urethral cream3 mg/g — on demand
O seu esquema é pessoal
Estes passos são apenas indicativos. O seu médico ajusta o plano à sua resposta e tolerância — e pode enviar-lhe uma mensagem em qualquer momento.
NO DIA A DIA
Usar Vitaros no dia a dia
Get shown the technique first
Every form of alprostadil has to be demonstrated by a medical professional before you use it yourself. For the injection and the urethral pellet the first doses are given or supervised in a clinic, not at home, and that step cannot be skipped.
Empty your bladder first
Urinate before using the cream or the pellet. A moist urethra helps the medicine dissolve and spread. Do not urinate straight after the cream, because the dose can be washed out before it has had time to work.
Cream sits at the opening
Roll the single-dose container between your hands to warm it, hold the penis upright and squeeze the tip to widen the opening. Place the container at the opening without inserting it, push all the cream in, then hold the penis upright for about 30 seconds.
Pellet needs a stretch and roll
For the urethral pellet, stretch the penis upward to its full length, insert the applicator, press the button and withdraw it. Then roll the penis between your hands for at least 10 seconds so the medicine coats the urethral wall.
Stand or walk for ten minutes
After the pellet, sit or preferably stand or walk for about 10 minutes while the erection develops. An erection usually appears 5 to 10 minutes after the pellet and lasts roughly 30 to 60 minutes. The cream works in 5 to 30 minutes.
Injections rotate side and site
The injection goes into the upper side of the penis, along the third nearest the body, avoiding visible veins. Change both the side and the exact spot each time. Never straighten or reuse a bent needle, because needles can break.
Use a condom if pregnancy is possible
A condom is required if your partner is pregnant or could become pregnant, and it also reduces vaginal irritation, which is a reported reaction. Only latex condoms have been tested with the cream. Alprostadil is not a contraceptive and does not prevent infection.
Respect the frequency limits
The cream is used at most 2 to 3 times a week and once in 24 hours. Injections are at most once a day and three times a week. The pellet is at most 2 doses in 24 hours and 7 in 7 days.
Segurança primeiro
A segurança, por inteiro.
Vitaros é um medicamento eficaz — e, como qualquer medicamento, acarreta riscos. O seu médico verifica tudo isto antes de prescrever. Este é o retrato honesto, não apenas palavras tranquilizadoras.
Efeitos secundários, por frequência
Stop and get urgent medical help if
seek medical help immediately
these need urgent attention, whatever the frequency
- An erection lasts 4 hours or more, which is priapism and a medical emergency that must not be left more than 6 hours
- Penile pain will not settle, or you notice a new bend, lump or hard patch in the penis
- You faint, feel close to fainting, or go dizzy with a sudden drop in blood pressure after a dose
- You get chest pain, or sudden weakness, numbness or trouble speaking
- Bleeding from the urethra will not stop, or there is blood in your urine
- Hives, a spreading rash or swelling appear, which can signal an allergic reaction
- A needle breaks and a fragment stays in the penis, which has needed surgical removal
Very common
very common (≥1/10)
more than 1 in 10 people
- Penile pain after intracavernosal injection, reported at least once by 30% of men and after 11% of injections
- Penile pain after the urethral pellet, in most cases rated mild or moderate
- Burning in the urethra after the urethral pellet
Common
common (≥1/100 to <1/10)
somewhere between 1 in 100 and 1 in 10 people
- Burning, tingling, throbbing or numbness in the penis, with the cream
- Redness, swelling, itching or general discomfort of the penis or genitals, with the cream
- Urethral pain with the cream, or minor urethral bleeding with the pellet
- An erection stronger or longer than expected, listed for all three forms
- Peyronie's disease, penile fibrosis, angulation or fibrotic nodules, with the injection and the pellet
- Bruising or a collection of blood at the injection site
- Headache, dizziness, symptomatic low blood pressure and muscle spasms, with the pellet
- Vaginal burning or itching in the partner, reported by about 6% of partners in the pellet studies
- Skin rash, with the cream
- Balanitis, inflammation of the head of the penis, with the cream
Uncommon
uncommon (≥1/1,000 to <1/100)
somewhere between 1 in 1,000 and 1 in 100 people
- Prolonged erection or priapism, listed at this frequency for all three forms
- Dizziness, fainting or a fall in blood pressure, listed for all three forms
- Painful erection, excessive rigidity, or loss of sensation in the penis
- Narrowing of the urethra, or inflammation of the urinary tract, with the cream
- Painful or frequent urination, urgency, blood in the urine or urethral bleeding
- Testicular or scrotal pain, swelling, redness or a lump, and pelvic or perineal pain
- Phimosis, ejaculation problems, or erectile dysfunction reported as a reaction
- Nausea, dry mouth, sweating, itching, rash, redness or a faster heartbeat
- Itching of the vulva or vagina in the partner, with the cream
- Widened pupils, extra heartbeats, a raised blood creatinine reading, or feeling weak
Rare
rare (≥1/10,000 to <1/1,000)
somewhere between 1 in 10,000 and 1 in 1,000 people
- Urinary tract infection, listed at this frequency for the urethral pellet
- Penile fibrosis, listed at this frequency for the urethral pellet
Very rare
very rare (<1/10,000)
fewer than 1 in 10,000 people
- Hives, known medically as urticaria, listed at this frequency for the urethral pellet
Frequency not known
not known (cannot be estimated from the available data)
reported after launch, but too rarely counted to put a number on
- Stroke, recorded in the injection product information as cerebrovascular accident
- Reduced blood supply to the heart muscle, recorded as myocardial ischaemia
Disfunção erétil em homens adultos, como alternativa local aos comprimidos.
- Aplique a dose de utilização única na abertura da ponta do pénis 5–30 minutos antes da relação, seguindo a técnica do folheto informativo.
- O efeito dura cerca de 1–2 horas.
- No máximo uma dose por 24 horas, e não mais de 2–3 doses por semana.
- Lave as mãos depois de aplicar.
QUEM NÃO DEVE TOMAR E QUEM PRECISA DE PRECAUÇÃO
- You have sickle-cell disease or sickle-cell trait, multiple myeloma or leukaemia, all of which predispose to priapism
- You have another condition predisposing to priapism, such as thrombocythaemia, polycythaemia, a tendency to venous thrombosis, a hyperviscosity syndrome, or past recurrent priapism
- You have a penile implant
- Your penis is anatomically deformed, including angulation, curvature, cavernosal fibrosis, Peyronie's disease or severe hypospadias
- You have urethritis or balanitis, or for the pellet a narrowing of the lower urethra
- You are allergic to alprostadil or to any other ingredient in the product
- A doctor has advised that sexual activity is inadvisable, for example with severe heart disease or unstable heart or circulation problems
- You have orthostatic hypotension, or a history of heart attack or fainting, which rule out the cream
- Your partner is pregnant or could become pregnant and a condom will not be used
- You are already using another erectile dysfunction treatment, including a PDE5 inhibitor tablet or another injected agent
Quando procurar cuidados urgentes
Perante sintomas graves, súbitos ou inesperados, ligue para o número de emergência local ou dirija-se às urgências mais próximas. Depois, informe o seu médico através do chat da sua conta.
Medicamentos e substâncias que interagem
| MEDICAMENTO OU SUBSTÂNCIA | O QUE PODE ACONTECER | O QUE FAZ O MÉDICO |
|---|---|---|
| PDE5 inhibitor tablets (sildenafil, tadalafil, vardenafil) | Never studied together; both act on blood vessels, so cardiovascular risk could add up | Not used together; the prescriber keeps you on one treatment at a time |
| Other injected erection agents (papaverine, phentolamine, thymoxamine) | Raises the risk of priapism, a painful prolonged abnormal erection | Not combined; alprostadil is prescribed on its own |
| Blood pressure medicines and other vasodilators | Blood pressure can fall further, and the risk is higher in older men | Prescribed with caution, with clear warning about dizziness and fainting |
| Anticoagulants and antiplatelet drugs (warfarin, heparin) | More bleeding after an injection, and more urethral bleeding or blood in the urine | Prescriber weighs the bleeding risk and may rule out the injected route |
| Sympathomimetics, decongestants and appetite suppressants | May reduce the effect of alprostadil, so a working dose can seem to fail | Prescriber reviews the full medicine list before changing any dose |
| Latex condoms | Only latex has been tested with the cream; other materials may be damaged by it | Use a latex condom, which is required anyway if a partner could be pregnant |
Peça a um médico para analisar o seu casoÉ exatamente isto que o médico verifica antes de prescrever seja o que for.
Leia o resumo de segurança completo de VitarosEVIDÊNCIA
O que os ensaios clínicos encontraram
In the two New England Journal of Medicine programmes that registered these products, the MUSE Study Group trial of the urethral pellet and the Alprostadil Study Group trials of intracavernosal injection, both routes produced erections firm enough for intercourse in most men who had first responded to a supervised test dose.
1,511 men aged 27 to 88 with chronic erectile dysfunction of organic cause · single clinic visit, up to four test doses
Transurethral alprostadil tested at 125, 250, 500 and 1000 micrograms
Fonte: Treatment of men with erectile dysfunction with transurethral alprostadil (MUSE Study Group)961 in-clinic responders who reported at least one home treatment · 3 months of home use
Transurethral alprostadil versus placebo, p<0.001; on average 7 of 10 doses were followed by intercourse
Fonte: Treatment of men with erectile dysfunction with transurethral alprostadil (MUSE Study Group)683 men in a self-injection study of intracavernosal alprostadil · 6 months
Patients and partners rated the activity satisfactory after 87% and 86% of injections
Fonte: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction (Alprostadil Study Group)the same 1,511-man transurethral alprostadil programme · clinic testing plus 3 months at home
The most common side effect; no man in that study had priapism or penile fibrosis
Fonte: Treatment of men with erectile dysfunction with transurethral alprostadil (MUSE Study Group)men across three multicentre intracavernosal alprostadil studies · up to 6 months of self-injection
Alongside prolonged erection in 5% and penile pain in 50% of men, after 11% of injections
Fonte: Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction (Alprostadil Study Group)These are group averages from trials, not a forecast for any one person. Both routes were screened in clinic first, and the home figures describe only the men who had already responded to that supervised test dose, so they read better than the result an unselected group would get. The European Association of Urology also records that 41% to 68% of men stop intracavernous injections, most within the first two to three months, and that only about 30% stay on the urethral pellet long term, which is a fair reminder that tolerating a treatment matters as much as its measured efficacy.
ALTERNATIVAS
Alprostadil vs the oral tablets usually tried first
| MEDICAMENTO | COMO SE ADMINISTRA | COM QUE FREQUÊNCIA | INTERVALO DE DOSE HABITUAL | INDICAÇÃO AUTORIZADA NA UE | EVIDÊNCIA PRINCIPAL |
|---|---|---|---|---|---|
| Sildenafil | Comprimido por via oral | Conforme necessário, máximo uma vez por dia | 25–100 mg | Erectile dysfunction in adult men; sexual stimulation is required | Dose-response study: improved erections 56%, 77%, 84% vs 25% placebo |
| Tadalafil | Comprimido por via oral | Conforme necessário, ou 5 mg uma vez por dia | 2.5–20 mg | Erectile dysfunction in adult males; sexual stimulation is required | Dose-response study: improved erections 67% and 81% vs 35% placebo |
| Vardenafil | Comprimido por via oral | Conforme necessário, máximo uma vez por dia | 5–20 mg | Erectile dysfunction in adult men; sexual stimulation is required | Dose-response study: improved erections 66%, 76%, 80% vs 30% placebo |
Não sabe qual se adequa ao seu caso? O médico analisa o seu historial e diz-lhe.
Iniciar consulta · 35 €ACESSO E CUSTO
Como obter Vitaros e quanto custa
Alprostadil is prescription-only in every EU country and no form of it is sold over the counter anywhere. Which form you can actually obtain varies a lot, so each row was read off that country's own medicines register rather than inferred from the EU-wide picture. The registers do not all publish the same thing: Spain, Portugal and Belgium record a marketing status per product, so those rows describe what is genuinely on sale, while Germany and Austria publish only whether an authorisation is currently valid, so their rows describe which forms are registered rather than which a pharmacy is stocking this week. Poland registers no alprostadil product for erectile dysfunction at all. The linked database is the current authority in every case.
O que paga à Hi-Doctor
35 € pontual
Responda a algumas perguntas e um médico licenciado na UE analisa o seu caso em menos de 2 horas, em média. Reembolso total se não for adequado para si.
O que a farmácia cobra
A Hi-Doctor não vende, não armazena nem dispensa medicamentos e não define o seu preço. O medicamento é pago à parte na farmácia e o valor depende do país, da embalagem, da existência de genérico e da comparticipação. A base de dados oficial ligada na tabela publica o preço autorizado em vigor.
| PAÍS | REGIME DE DISPENSA | COMPARTICIPADO PELO SISTEMA DE SAÚDE? | FONTE OFICIAL |
|---|---|---|---|
| Espanha | Medicamento sujeito a receita médica; a injeção tem uma restrição de diagnóstico hospitalar | See national criteria | AEMPS CIMA |
Ver os outros países
| Alemanha | Medicamento sujeito a receita médica; injeção, bastonete uretral e creme têm todos autorização válida | Excluded from statutory health insurance | PharmNet.Bund AMIce |
|---|---|---|---|
| França | Medicamento sujeito a receita médica; as injeções são liste I | Restricted — only for the organic causes listed in the official decision | Base de données publique des médicaments |
| Itália | Medicamento sujeito a receita médica; é necessário um plano terapêutico especializado para a comparticipação | Restricted — AIFA Nota 75, intracavernosal injection only | AIFA Medicinali |
| Países Baixos | Medicamento sujeito a receita médica | See national criteria | CBG-MEB Geneesmiddeleninformatiebank |
| Portugal | Medicamento sujeito a receita médica (MSRM); a injeção e o creme têm cada um pelo menos uma apresentação comercializada | See national criteria | INFARMED Infomed |
| Bélgica | Medicamento sujeito a receita médica; a injeção e o creme estão comercializados, o cartucho de dupla câmara não | See national criteria | FAGG-AFMPS medicines database |
| Irlanda | Medicamento sujeito a receita médica | See national criteria | HPRA Find a Medicine |
| Áustria | Medicamento sujeito a receita médica (Rp); o bastonete uretral está registado como comercializado, a injeção e o creme como autorizados | See national criteria | BASG Medikamente Info Austria |
| Polónia | Não comercializado | — | Rejestr Produktów Leczniczych |
PREÇOS
Só paga se o tratamento for aprovado.
35 € por uma consulta de saúde sexual. Pagamento único, sem cobranças recorrentes.
Saúde sexual
PAGAMENTO ÚNICO
35 € pontual
Uma consulta, um médico, uma decisão.
Nada é guardado publicamente, nunca
Iniciar consulta
Reembolso total se uma avaliação não for aprovada
O QUE ESTÁ INCLUÍDO
- Consulta revista por um médico licenciado na UE
- Receita eletrónica em caso de aprovação
- Reembolso total em caso de recusa
Reembolso total se uma avaliação não for aprovada
Se uma avaliação não for aprovada, devolvemos integralmente a taxa de consulta de 35 €.
Nota: A medicação, se o médico a prescrever, é paga separadamente na farmácia ao preço que esta definir. A Hi-Doctor não vende medicamentos.
COMO DECIDE O MÉDICO
Um médico inscrito na Ordem analisa o seu caso, não um algoritmo
Um médico habilitado na UE lê o seu questionário e responde em menos de 2 horas, em média.
Se o médico decidir que não é seguro prescrever, o valor da consulta é reembolsado na íntegra.
O acompanhamento decorre no chat privado da sua conta, em conformidade com o RGPD. Sem WhatsApp, sem SMS.
PERGUNTAS FREQUENTES
Perguntas sobre Vitaros.
OUTROS TRATAMENTOS DE SAÚDE SEXUAL
Explore tratamentos relacionados.
FONTES
De onde vem esta informação
- 01
Vitaros 3 mg/g cream: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 02
Caverject Dual Chamber 20 micrograms: Summary of Product Characteristics — electronic medicines compendium (emc), 2026
- 03
MUSE 500 microgramos bastoncillo uretral: Ficha Técnica — AEMPS, Spain, 2016
- 04
Treatment of men with erectile dysfunction with transurethral alprostadil (MUSE Study Group) — New England Journal of Medicine 336(1):1-7, 1997
- 05
Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction (Alprostadil Study Group) — New England Journal of Medicine 334(14):873-7, 1996
- 06
EAU Guidelines on Sexual and Reproductive Health, limited update March 2025 — European Association of Urology, 2025
- 07
Alprostadil: authorised medicines register (Caverject, Virirec and alprostadil cream marketed; MUSE authorised but not marketed) — AEMPS CIMA, Spain, 2026
- 08
Alprostadil: Vitaros 300 microgrammes cream and Edex 10/20 microgrammes marketed, liste I, restricted reimbursement — Base de données publique des médicaments, France, 2026
- 09
Alprostadil products authorised in Ireland: Caverject 10 and 20 micrograms, Vitaros 3 mg/g cream — medicines.ie, Irish medicines compendium, 2026
- 10
Register of medicinal products: no ATC G04BE01 alprostadil product registered for erectile dysfunction — Rejestr Produktów Leczniczych, Poland, 2026
- 11
Nota 75: reimbursement of alprostadil by intracavernosal injection limited to defined neurological criteria — AIFA, Gazzetta Ufficiale della Repubblica Italiana n. 7, 2017
- 12
§ 34 SGB V: medicines predominantly for erectile dysfunction excluded from statutory health insurance — Bundesministerium der Justiz, Germany, 2026
- 13
Regeling zorgverzekering: MUSE urethral stick 125 to 1000 micrograms listed on the Dutch medicines annex — Wetten.overheid.nl, Netherlands, 2026
- 14
Viagra (sildenafil): Summary of Product Characteristics, Annex I — European Medicines Agency, 2025
- 15
Cialis (tadalafil): Summary of Product Characteristics, Annex I — European Medicines Agency, 2025
- 16
Levitra (vardenafil): Summary of Product Characteristics, Annex I — European Medicines Agency, 2024
- 17
Alprostadil, human medicines with a currently valid German authorisation: Caverject and Caverject Impuls 10 and 20 micrograms (Pfizer Pharma GmbH plus parallel importers), Muse 500 and 1000 micrograms (Viatris Healthcare GmbH), Vitaros 300 micrograms/100 mg cream (The Simple Pharma Company Limited). The register publishes marketability, not whether a product is currently distributed. — BfArM AMIce, public part, via PharmNet.Bund, Germany, 2026
- 18
Alprostadilo: Caverject 0,01 and 0,02 mg/ml (Laboratórios Pfizer, Lda.) and Vitaros cream 0,3 mg/100 mg (Recordati Ireland Ltd.), each authorised with at least one marketed presentation — INFARMED Infomed, Portugal, 2026
- 19
Alprostadil: Caverject 10 and 20 micrograms and Vytaros 3 mg/g cream recorded as commercialised; Caverject Impuls 10 and 20 micrograms recorded as not commercialised — FAGG-AFMPS medicines database, Belgium, 2026
- 20
Alprostadil, ATC G04BE01: Muse 250, 500 and 1000 micrograms recorded as marketed; Caverject, Caverject Dual and Vitaros 3 mg/g cream authorised, with no marketing status published — BASG Medikamente Info Austria, Arzneispezialitätenregister, 2026
Revisto pela equipa médica da Hi-Doctor · Última revisão 2026-07-27 · Próxima revisão prevista em 2027-07-27
Esta página contém informação sobre um medicamento; não é uma recomendação para o tomar nem substitui uma consulta médica. Só um médico habilitado que tenha analisado o seu historial pode decidir se um tratamento é adequado para si.
Descubra se é adequado para si
Veja se Vitaros é apropriado para si.
Responda a algumas perguntas e um médico licenciado na UE analisa o seu caso em menos de 2 horas, em média. Reembolso total se não for adequado para si.